Alzamend Neuro Q1 EPS Lifted by Ascendiant Capital Markets

Alzamend Neuro, Inc. (NASDAQ:ALZN) – Equities researchers at Ascendiant Capital Markets lifted their Q1 2027 EPS estimates for Alzamend Neuro in a research report issued to clients and investors on Tuesday, August 18th. Ascendiant Capital Markets analyst E. Woo now expects that the company will earn ($0.56) per share for the quarter, up from their previous estimate of ($0.67). The consensus estimate for Alzamend Neuro’s current full-year earnings is ($2.60) per share. Ascendiant Capital Markets also issued estimates for Alzamend Neuro’s Q2 2027 earnings at ($0.23) EPS, Q3 2027 earnings at ($0.22) EPS, Q4 2027 earnings at ($0.22) EPS and FY2027 earnings at ($1.05) EPS.

Separately, Weiss Ratings downgraded Alzamend Neuro from a “sell (e+)” rating to a “sell (e)” rating in a research note on Monday, August 17th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Alzamend Neuro presently has an average rating of “Hold” and a consensus price target of $28.00.

Alzamend Neuro Stock Down 0.6%

Shares of Alzamend Neuro stock opened at $1.55 on Tuesday. The stock has a market capitalization of $7.42 million, a price-to-earnings ratio of -0.53 and a beta of 0.16. Alzamend Neuro has a twelve month low of $0.84 and a twelve month high of $2.68. The company has a 50-day simple moving average of $1.32 and a two-hundred day simple moving average of $1.38.

Alzamend Neuro (NASDAQ:ALZN) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.07).

Institutional Investors Weigh In On Alzamend Neuro

An institutional investor recently raised its position in Alzamend Neuro stock. Geode Capital Management LLC lifted its holdings in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) by 33.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,506 shares of the company’s stock after buying an additional 6,928 shares during the quarter. Geode Capital Management LLC owned about 0.72% of Alzamend Neuro worth $50,000 at the end of the most recent quarter. Institutional investors own 49.61% of the company’s stock.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.